Elanco Animal Health Incorporated

Elanco Animal Health Incorporated

26.41
USD
-0.37
(-1.38%)
-0.29EPS
11.19BMarket Cap
Mar 02Next Earn

Total Valuation

USD

As of September 30, 2026, Elanco Animal Health Incorporated carries a market capitalization of 11.19B, placing it among publicly traded companies globally. Its enterprise value stands at 14.43B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap11.19B
Enterprise Value14.43B

Important Dates

Elanco Animal Health Incorporated's next confirmed earnings release is scheduled for March 2, 2027.

Earnings Date3/2/2027

Share Statistics

As of September 30, 2026, Elanco Animal Health Incorporated has 499.73M shares outstanding.

Shares Outstanding499.73M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 2.17, and the price-to-book ratio stands at 1.69.

PS Ratio2.17
PB Ratio1.69
P/TBV Ratio-9.32
P/FCF Ratio27.65
P/OCF Ratio18.18

Enterprise Valuation

As of September 30, 2026, Elanco Animal Health Incorporated trades at an EV/EBITDA multiple of 16.90 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.80 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 90.19 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 14.43B versus a market cap of 11.19B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales2.80
EV / EBITDA16.90
EV / EBIT90.19

Financial Position

As of September 30, 2026, Elanco Animal Health Incorporated maintains a current ratio of 2.09, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 55.93, indicating elevated leverage, while an interest coverage ratio of 3.35 demonstrates adequate ability to service its debt obligations.

Current Ratio2.09
Quick Ratio0.86
Debt / Equity55.93
Debt / EBITDA4.34
Interest Coverage3.35

Financial Efficiency

USD

Over the twelve months ended September 30, 2026, Elanco Animal Health Incorporated posted a negative return on equity (ROE) of -2.20, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.09, reflecting losses generated across the asset base. The company generates approximately 520,000.00 in revenue per employee across its workforce of 9,900.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.28 indicates how many times Elanco Animal Health Incorporated sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-2.20
Return on Assets (ROA)-1.09
Revenue Per Employee520,000.00
Employee Count9,900.00
Inventory Turnover1.28

Taxes

USD

Over the twelve months ended September 30, 2026, Elanco Animal Health Incorporated recorded 55.00M in income tax expense. The company reported a pretax loss of -92.00M and -147.00M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax55.00M

Stock Price Statistics

USD

As of the close on November 16, 2026, Elanco Animal Health Incorporated's stock has gained approximately 25.23% over the past 52 weeks. The 50-day moving average sits at 23.42, while the 200-day moving average is 23.87.

52-Week Price Change25.23%
50-Day Moving Average23.42
200-Day Moving Average23.87

Income Statement

USD

Over the twelve months ended September 30, 2026, Elanco Animal Health Incorporated generated 5.15B in revenue and converted that into -147.00M in net income, yielding earnings per share of -0.29. EBITDA reached 854.00M, while operating income came in at 390.00M.

Revenue5.15B
Gross Profit2.89B
Operating Income390.00M
Pretax Income-92.00M
Net Income-147.00M
EBITDA854.00M
EBIT160.00M
Earnings Per Share (EPS)-0.29

Balance Sheet

USD

As of September 30, 2026, Elanco Animal Health Incorporated holds 465.00M in cash and equivalents against 3.71B in total debt, resulting in a net debt position of 3.24B. Total book value stands at 6.63B, with working capital of 1.94B providing operational flexibility.

Cash & Cash Equivalents465.00M
Total Debt3.71B
Net Debt3.24B
Equity (Book Value)6.63B
Book Value Per Share13.26
Working Capital1.94B

Cash Flow

USD

Elanco Animal Health Incorporated produced 614.00M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -206.00M in capital expenditures, free cash flow totaled 408.00M - equivalent to 0.82 per share.

Operating Cash Flow614.00M
Capital Expenditures-206.00M
Free Cash Flow408.00M
FCF Per Share0.82

Margins

Over the twelve months ended September 30, 2026, Elanco Animal Health Incorporated posted a gross margin of 56.18, reflecting its pricing power and cost economics. The operating margin of 7.58 and net profit margin of -2.86 provide insight into operational efficiency.

Gross Margin56.18
Operating Margin7.58
Pretax Margin-1.79
Profit Margin-2.86
EBITDA Margin16.59

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield stands at 3.62, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 3.33, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Elanco Animal Health Incorporated shareholders.

Shareholder Yield3.33
FCF Yield3.62

Scores

As of September 30, 2026, Elanco Animal Health Incorporated has an Altman Z-Score of 2.07, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.07